JS PD KB

Biobanks in Japan tail (Tsukuba1 + Kyoto-U Nagahama phase0), 20231009 Hooki Tsmurni Niigata univ, BWMVRINER NSTM BM Tracking (KPI) matrix, GBA Activity / GBM / GACer assay rows, CSF Sample (Sato) prototype, CSF & NDE row, ARM lysosomal marker discussion

5 min read

Biobanks in Japan tail (Tsukuba1 + Kyoto-U Nagahama phase0), 20231009 Hooki Tsmurni Niigata univ, BWMVRINER NSTM BM Tracking (KPI) matrix, GBA Activity / GBM / GACer assay rows, CSF Sample (Sato) prototype, CSF & NDE row, ARM lysosomal marker discussion

Biobanks in Japan (continued)

content
CollabTsukuba 1 biobank Okayama-U biobank Serum/Plasma/Blood/PBMC/Tissues 167,116 specimens
MTA/CollabKyoto-U Nagahama phase0 cohort http://zeroji-cohort.com/ DNA/RNA/Serum/Plasma/Urine ICD-10 disease including dementia 6,200 case 10,082 registrants

20231009 Hooki Tsmurni Niigata univ

  • Potential for sPD
  • Will they plan to reverse to add Parkin?
  • How many biopsy?
  • Current contract open to CSF (Sami)?
  • ~$50,000 spend?
  • MBMs not included WCT
  • Patient already available or need to buy?
  • Submitted to NJFP
  • Budget source QTS Picosin NSTM

BWMVRINER NSTM BM Tracking (KPI)

https://www.bmer.fr Biomarker Tracking

(The matrix is reproduced as a single dense block; the per-row biomarker development plan is preserved verbatim in format_notes because the source uses dense colour-coded cells across many narrow columns.)

rowcontent
GBA Activity (DPK BX)BX Otake stained RD DDU “No pou conformed that this can detect activity” or detectability of CSF (samples) where the human GBA may not be at low (CSF Otake) (#JR60 BFA) 20210908 has a poster - new analysis
GBA mRNA (CSF)Otake
GBA activity (in parallel)252 / 2020 SEP / Establish study plan / Determine assay sensitivity, linearity, storage conditions etc / 2021 SEP detectability confirmed (we only confirmed the fluorescent value obtained from CSF was just above blank value, ie no LOQ 8) / 20231114 Otake detectability confirmed in pooled CSF but sensitivity is lower than that of Praxis’s so we are improving sensitivity / 20240218 Otake assays of HCs and 2 PD subjects in duplicate but he performed three in duplicate at 100 µl each / 2021 May / Modulation of bind compound in iPSC-derived DA neurons (in vitro calibration testing rodent or NHP samples)
GBM activity (in parallel) (Beam medi)2020 SEP take meta / Work began FY17 / Initial method developed although qualification in nature / @ FY18 / Update biomarker label standards are available in TS HQ DMM (need a fully quantitative assay) / 22-FY20 (KP1) extends the SOP to TS HQ for the studies in vivo and in vivo Iso human (J7) (KP1 Apr/PEPK 11 Mike)
GACer (CSF as PK strategy)red workhop CSF/Mac PK measure data 일정 (Polo, Joaquin) 2020/03 (Otake) Pre-finished (PK strategy)
GlcSph (PK strategy)20210625 Otake the required volume for GlcCer is 100 μL / 2020 / cross / 2020 / 2020 SEP take a 1-S Assay Detection in normal human (samples) / Otake sample volume in PFE in iPSC and NHP/DA
An so PV (Determine measured PV / J20.0%) (J20 dn iPSC1 in normal human GBA Pl 2 BSA increased in P0 (5) / Concept of pre-trained models / 2021/11/15 (we, monkey CSF) M01 Pole-trained models (Detected and CSF measure value to do PK fix and was monkey CSF Pl 0.5 pg/ml. We don’t think any low and human GBA value (Pole-trained PD CSF) is reasonable for the establishment of healthy donor and PD patients in the future…)
20210127 Otake Pre-trained in normal human samples (Otake sample volume in iPSC)
20211118 Otake Pre-trained 0.5 pg/ml in CSF, 0.05 ng/ml in plasma and 0.3 ng/ml in plasma (Otake-san: An so PV 0.4 mg/ml is reasonable based on Praxis’s report)
In healthy humans is considerably low. (1.07 - 0.79 pg/ml)
20230907 Detected and 0.05 pg/ml in CSF Pl 0.0 ng/ml in plasma and 0.05 ng/ml in plasma (Otake-san) we already succeeded in measuring CSF GlcSph only collecting at 1.2 µL

CSF Sample (Sato)

  • only have a prototype assay for sCSP-Ab of FE or just before PE we will investigate assay quality applicable in clinic
  • Method established shown by the analysis of the establishing Demai’s protocol
  • Established in BIOTV
  • Detection of synthesized internal standard will be tested with cyno matrix from BIOTV
  • In vitro calibration testing rodent or NHP samples

CSF & NDE

2132020 SEP / Establish study plan / Determine assay sensitivity, linearity, storage conditions etc
Cat Dr Stand from Brigham 1d6450-302 (a fluoroswan-based assay using probes), substrate.2021 May / Modulation of test compound in iPSC-derived DA neurons (achieved sensitivity LOQ and accuracy)
20210117/2021 year initial review BFA achieved20210817/2021 year initial review BFA achieved
20240608 OtakeLOQ 20240218 Otake (LOQ in CSF as activity assays Reuters: 50 of CSF and 50 µl for plasma in duplicate but he performed three in duplicate)
20240403 SatoWe already succeeded in measuring CSF GlcSph only collecting at 1-2 µL

ARM/I 까 한 건치 우리 정요 외라 ARM measures Hox 70, Lamp1 & 2nx Lamp2 in disease model (PD) and animal model) (By WB) (BM discovery) sample 가급 Eslau Sugita for ph.

  • Direction of lysosomal marker changes may be affected by disease stage of PD
  • Beclin이 증가해서 proteolysis가 정상적이면, 치료로 이거 낮추면 무슨 의미?
  • lysosomal (marker) changes in a broader context
  • global protein degradation

그래프 뷰

백링크